1
|
Wang J, Liu S, Lin M, Chen P, Yi H, Lv Z, Liu Y. Fabricating Oral Disintegrating Tablets Without Disintegrant Using Powder-Based 3D Printing. Pharmaceutics 2025; 17:435. [PMID: 40284430 PMCID: PMC12030749 DOI: 10.3390/pharmaceutics17040435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2025] [Revised: 03/21/2025] [Accepted: 03/22/2025] [Indexed: 04/29/2025] Open
Abstract
Background: Powder-based 3D printing, an advanced additive manufacturing technique, can produce oral disintegrating tablets (ODTs) without disintegrants, creating larger-pored tablets via layer-by-layer powder stacking for better water absorption than traditional tablets. Methods: This study focused on using powder-based 3D printing to fabricate clozapine-based ODTs. Through central composite design (CCD), the formulation of ODTs was optimized for rapid disintegration. Analytical techniques such as X-ray Powder Diffraction (XRD), Fourier Transform Infrared Spectroscopy (FTIR), and Differential Scanning Calorimetry (DSC) were employed to investigate the compatibility between clozapine and excipients. Results: The optimized 3D-printed ODTs exhibited a remarkably short disintegration time of (9.9 ± 0.7) s compared to (40) s for compressed tablets. The contact angle of the 3D-printed ODTs was measured as 60.48 ± 0.36°, indicating favorable wettability for disintegration. Scanning Electron Microscopy (SEM) analysis revealed a porous structure in 3D-printed tablets, with a porosity of 48.97% (over two times higher than that of compressed tablets as determined by mercury injection meter). Conclusions: Collectively, this finding demonstrates the feasibility of fabricating highly hydrophilic and non-distensible ODTs without disintegrants using powder-based 3D printing.
Collapse
Affiliation(s)
- Jiu Wang
- Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, Center for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China; (J.W.); (M.L.); (H.Y.)
- Guangdong High Education Institutes Engineering Research Center of Modified-Released Pharmaceutical Products, School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
- Guangdong Provincial Engineering Center of Topical Precision Drug Delivery System, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Shunfang Liu
- Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, Center for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China; (J.W.); (M.L.); (H.Y.)
- Guangdong High Education Institutes Engineering Research Center of Modified-Released Pharmaceutical Products, School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
- Guangdong Provincial Engineering Center of Topical Precision Drug Delivery System, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Minmei Lin
- Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, Center for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China; (J.W.); (M.L.); (H.Y.)
- Guangdong Provincial Engineering Center of Topical Precision Drug Delivery System, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
- Jieyang People’s Hospital, Jieyang 522000, China
| | - Peihong Chen
- Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, Center for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China; (J.W.); (M.L.); (H.Y.)
- Guangdong High Education Institutes Engineering Research Center of Modified-Released Pharmaceutical Products, School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
- Guangdong Provincial Engineering Center of Topical Precision Drug Delivery System, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Huagui Yi
- Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, Center for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China; (J.W.); (M.L.); (H.Y.)
- Guangdong High Education Institutes Engineering Research Center of Modified-Released Pharmaceutical Products, School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
- Guangdong Provincial Engineering Center of Topical Precision Drug Delivery System, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Zhufen Lv
- Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, Center for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China; (J.W.); (M.L.); (H.Y.)
- Guangdong High Education Institutes Engineering Research Center of Modified-Released Pharmaceutical Products, School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
- Guangdong Provincial Engineering Center of Topical Precision Drug Delivery System, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
| | - Yuanfen Liu
- Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations, Center for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China; (J.W.); (M.L.); (H.Y.)
- Department of Pharmacy, Jiangsu Health Vocational College, Nanjing 211800, China
| |
Collapse
|
2
|
Nyavanandi D, Mandati P, Vidiyala N, Parupathi P, Kolimi P, Mamidi HK. Enhancing Patient-Centric Drug Development: Coupling Hot Melt Extrusion with Fused Deposition Modeling and Pressure-Assisted Microsyringe Additive Manufacturing Platforms with Quality by Design. Pharmaceutics 2024; 17:14. [PMID: 39861666 PMCID: PMC11769097 DOI: 10.3390/pharmaceutics17010014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2024] [Revised: 12/22/2024] [Accepted: 12/24/2024] [Indexed: 01/27/2025] Open
Abstract
In recent years, with the increasing patient population, the need for complex and patient-centric medications has increased enormously. Traditional manufacturing techniques such as direct blending, high shear granulation, and dry granulation can be used to develop simple solid oral medications. However, it is well known that "one size fits all" is not true for pharmaceutical medicines. Depending on the age, sex, and disease state, each patient might need a different dose, combination of medicines, and drug release pattern from the medications. By employing traditional practices, developing patient-centric medications remains challenging and unaddressed. Over the last few years, much research has been conducted exploring various additive manufacturing techniques for developing on-demand, complex, and patient-centric medications. Among all the techniques, nozzle-based additive manufacturing platforms such as pressure-assisted microsyringe (PAM) and fused deposition modeling (FDM) have been investigated thoroughly to develop various medications. Both nozzle-based techniques involve the application of thermal energy. However, PAM can also be operated under ambient conditions to process semi-solid materials. Nozzle-based techniques can also be paired with the hot melt extrusion (HME) process for establishing a continuous manufacturing platform by employing various in-line process analytical technology (PAT) tools for monitoring critical process parameters (CPPs) and critical material attributes (CMAs) for delivering safe, efficacious, and quality medications to the patient population without compromising critical quality attributes (CQAs). This review covers an in-depth discussion of various critical parameters and their influence on product quality, along with a note on the continuous manufacturing process, quality by design, and future perspectives.
Collapse
Affiliation(s)
- Dinesh Nyavanandi
- Small Molecule Drug Product Development, Cerevel Therapeutics, Cambridge, MA 02141, USA;
| | - Preethi Mandati
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38677, USA; (P.M.); (P.K.)
| | - Nithin Vidiyala
- Small Molecule Drug Product Development, Cerevel Therapeutics, Cambridge, MA 02141, USA;
| | - Prashanth Parupathi
- Division of Pharmaceutical Sciences, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY 11201, USA;
| | - Praveen Kolimi
- Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38677, USA; (P.M.); (P.K.)
| | | |
Collapse
|
3
|
Firdous SO, Sagor MMH, Arafat MT. Advances in Transdermal Delivery of Antimicrobial Peptides for Wound Management: Biomaterial-Based Approaches and Future Perspectives. ACS APPLIED BIO MATERIALS 2024; 7:4923-4943. [PMID: 37976446 DOI: 10.1021/acsabm.3c00731] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2023]
Abstract
Antimicrobial peptides (AMPs), distinguished by their cationic and amphiphilic nature, represent a critical frontier in the battle against antimicrobial resistance due to their potent antimicrobial activity and a broad spectrum of action. However, the clinical translation of AMPs faces hurdles, including their susceptibility to degradation, limited bioavailability, and the need for targeted delivery. Transdermal delivery has immense potential for optimizing AMP administration for wound management. Leveraging the skin's accessibility and barrier properties, transdermal delivery offers a noninvasive approach that can circumvent systemic side effects and ensure sustained release. Biomaterial-based delivery systems, encompassing nanofibers, hydrogels, nanoparticles, and liposomes, have emerged as key players in enhancing the efficacy of transdermal AMP delivery. These biomaterial carriers not only shield AMPs from enzymatic degradation but also provide controlled release mechanisms, thereby elevating stability and bioavailability. The synergistic interaction between the transdermal approach and biomaterial-facilitated formulations presents a promising strategy to overcome the multifaceted challenges associated with AMP delivery. Integrating advanced technologies and personalized medicine, this convergence allows the reimagining of wound care. This review amalgamates insights to propose a pathway where AMPs, transdermal delivery, and biomaterial innovation harmonize for effective wound management.
Collapse
Affiliation(s)
- Syeda Omara Firdous
- Department of Biomedical Engineering, Bangladesh University of Engineering and Technology (BUET), Dhaka 1205, Bangladesh
| | - Md Mehadi Hassan Sagor
- Department of Biomedical Engineering, Bangladesh University of Engineering and Technology (BUET), Dhaka 1205, Bangladesh
| | - M Tarik Arafat
- Department of Biomedical Engineering, Bangladesh University of Engineering and Technology (BUET), Dhaka 1205, Bangladesh
| |
Collapse
|
4
|
Han MJ, Zou ZZ. Enabling a novel solvent method on Albendazole solid dispersion to improve the in vivo bioavailability. Eur J Pharm Sci 2024; 196:106751. [PMID: 38508502 PMCID: PMC11055451 DOI: 10.1016/j.ejps.2024.106751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2023] [Revised: 03/14/2024] [Accepted: 03/15/2024] [Indexed: 03/22/2024]
Abstract
Albendazole, a vital medication endorsed by the World Health Organization for combating parasitic infections, encounters a challenge stemming from its low solubility, significantly impeding absorption and bioavailability. Albendazole has near-insolubility in most organic solvents, so the solid dispersions of albendazole were predominantly using the fusion method. However, the solvent method could offer the advantage of achieving molecular-level mixing homogeneity. In this investigation, we incorporated the pH adjustment to prepare albendazole solid dispersion using a solvent method, which utilizes trace amounts of HCl in methanol, yielding notably enhanced albendazole solubility. Subsequently, carriers such as PEG6000/Poloxamer 188 (PEG: polyethylene glycol) and PVP K30/Poloxamer 188 (PVP: polyvinylpyrrolidone) were employed to create albendazole solid dispersions. Comprehensive characterization through dissolution rate analysis, PXRD (Powder X-ray diffraction), SEM (Scanning electron microscopy), DSC (differential scanning calorimetry), and pharmacokinetic (PK) studies in mice and rats was conducted. The findings indicate that the solid dispersion effectively transforms the crystalline state of albendazole into an amorphous state, resulting in significantly enhanced in vivo absorption and a 5.9-fold increase in exposure. Besides, the exposure increased 1.64 times of commercial albendazole tablets. Notably, PEG6000/Poloxamer 188 and PVP K30/Poloxamer 188 solid dispersions exhibited superior dissolution rates and pharmacokinetic profiles compared to commercially available albendazole tablets.
Collapse
Affiliation(s)
- Ming-Jie Han
- Department of DMPK, Global Health Drug Discovery Institute, Zhongguancun Dongsheng International Science Park, Beijing, PR China.
| | - Zhiyang Zack Zou
- Department of DMPK, Global Health Drug Discovery Institute, Zhongguancun Dongsheng International Science Park, Beijing, PR China.
| |
Collapse
|
5
|
Lenzuni M, Fiorentini F, Summa M, Bertorelli R, Suarato G, Perotto G, Athanassiou A. Electrosprayed zein nanoparticles as antibacterial and anti-thrombotic coatings for ureteral stents. Int J Biol Macromol 2024; 257:128560. [PMID: 38061505 DOI: 10.1016/j.ijbiomac.2023.128560] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Revised: 10/29/2023] [Accepted: 11/30/2023] [Indexed: 12/18/2023]
Abstract
Ureteral stents are among the most frequently used human implants, with urothelium trauma, blood clots, and bacterial colonization being their main reasons for failure. In this study, berberine-loaded zein (ZB) nanoparticles with high drug encapsulation efficiency (>90 %) were fabricated via electrospray on flat and 3D stainless steel structures. Physico-chemical characterization revealed that the ZB nanoparticles created a highly hydrophilic, antioxidant, and scratch-resistant continuous coating over the metal structure. Results showed that the drug release rate was faster at neutral pH (i.e., PBS pH 7.4) than in an artificial urine medium (pH 5.3) due to the different swelling behavior of the zein polymeric matrix. In vitro evaluation of ZB particles onto human dermal fibroblasts and blood cells demonstrated good cell proliferation and enhanced anti-thrombotic properties compared to bare stainless steel. The ability of the electrosprayed zein particles to resist bacterial adherence and proliferation was evaluated with Gram-negative (Escherichia coli) bacteria, showing high inhibition rates (-29 % and -46 % for empty and berberine-loaded particles, respectively) compared to the medical-grade metal substrates. Overall, the proposed composite coating fulfilled the requirements for ureteral applications, and can advance the development of innovative biocompatible, biodegradable, and antibacterial coatings for drug-eluting stents.
Collapse
Affiliation(s)
- Martina Lenzuni
- Smart Materials Group, Istituto Italiano di Tecnologia, Genoa, Italy; Department of Civil, Chemical and Environmental Engineering, University of Genoa, Genoa, Italy.
| | | | - Maria Summa
- Translational Pharmacology, Istituto Italiano di Tecnologia, Genoa, Italy
| | - Rosalia Bertorelli
- Translational Pharmacology, Istituto Italiano di Tecnologia, Genoa, Italy
| | - Giulia Suarato
- Consiglio Nazionale delle Ricerche, Istituto di Elettronica, Ingegneria dell'Informazione e delle Telecomunicazioni (CNR-IEIIT), Milan, Italy
| | - Giovanni Perotto
- Smart Materials Group, Istituto Italiano di Tecnologia, Genoa, Italy
| | | |
Collapse
|
6
|
Ibanescu A, Olariu DI, Lutic D, Hulea V, Dragoi B. Engineering the Morphostructural Properties and Drug Loading Degree of Organic-Inorganic Fluorouracil-MgAl LDH Nanohybrids by Rational Control of Hydrothermal Treatment. ACS OMEGA 2023; 8:26102-26121. [PMID: 37521604 PMCID: PMC10372945 DOI: 10.1021/acsomega.3c02288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 06/13/2023] [Indexed: 08/01/2023]
Abstract
Layered double hydroxides (LDHs) or hydrotalcite-like compounds have attracted great attention for the delivery of anticancer drugs due to their 2D structure, exhibiting a high surface-to-volume ratio and a high chemical versatility. The drug is protected between the layers from which it is slowly released, thus increasing the therapeutic effect and minimizing the side effects associated to nonspecific targeting. This work aimed to design LDHs with Mg and Al (molar ratio of 2/1) in brucite-like layers, which retained fluorouracil (5-FU; 5-FU/Al = 1, molar ratio) in the interlayer gallery as the layers grow during the co-precipitation step of the synthesis. To rationally control the physicochemical properties, particularly the size of the crystallites, the aging step following the co-precipitation was performed under carefully controlled conditions by changing the time and temperature (i.e., 25 °C for 16 h, 100 °C for 16 h, and 120 °C for 24 h). The results revealed the achievement of the control of the size of the crystals, which are gathered in three different agglomeration systems, from tight to loose, as well as the loading degree of the drug in the final organic-inorganic hybrid nanomaterials. The role played by the factors and parameters affecting the drug-controlled release was highlighted by assessing the release behavior of 5-FU by changing the pH, solid mass/volume ratio, and ionic strength. The results showed a pH-dependent behavior but not necessarily in a direct proportionality. After a certain limit, the mass of the solid diminishes the rate of release, whereas the ionic strength is essential for the payload discharge.
Collapse
Affiliation(s)
- Alina Ibanescu
- TRANSCEND
Research Center, Regional Institute of Oncology, 2-4 General Henri Mathias Berthelot, 700483 Iasi, Romania
- Faculty
of Chemical Engineering and Environmental Protection, “Gheorghe Asachi” Technical University of Iasi, 73 Prof. D. Mangeron Bvd., 700050 Iasi, Romania
| | - Dragos-Ioan Olariu
- TRANSCEND
Research Center, Regional Institute of Oncology, 2-4 General Henri Mathias Berthelot, 700483 Iasi, Romania
- Faculty
of Chemistry, Al. I. Cuza University, 11-Carol I Bvd., 700506 Iasi, Romania
| | - Doina Lutic
- TRANSCEND
Research Center, Regional Institute of Oncology, 2-4 General Henri Mathias Berthelot, 700483 Iasi, Romania
- Faculty
of Chemistry, Al. I. Cuza University, 11-Carol I Bvd., 700506 Iasi, Romania
| | - Vasile Hulea
- Institut
Charles Gerhardt Montpellier, UMR 5253, CNRS-UM-ENSCM,Montpellier 34296, France
| | - Brindusa Dragoi
- TRANSCEND
Research Center, Regional Institute of Oncology, 2-4 General Henri Mathias Berthelot, 700483 Iasi, Romania
- Faculty
of Chemistry, Al. I. Cuza University, 11-Carol I Bvd., 700506 Iasi, Romania
| |
Collapse
|